AUTL · Autolus Therapeutics plc · Metrics
Market Cap
$493.73M
Shares
266.16M
Volume · Oct 1
947.27K
Avg daily vol (3M)
2.04M
AUTL metrics
61 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$1.94
Market cap
$493.73M
Price action
20 metricsPrice change (1W)
-0.5%
Price change (30D)
-16.0%
Price change (3M)
+22.8%
Price change (6M)
+40.6%
Price change (YTD)
-2.5%
Price change (1Y)
+19.0%
Trailing year
Price change (5Y)
-70.4%
52-week high
$2.54
52-week low
$1.21
Change from 52-week high
-23.6%
Change from 52-week low
+60.3%
Annualized volatility
77.4%
Annualized volatility (3M)
79.1%
Beta
1.9
RSI (14D)
46.4
Price vs SMA 50
-3.6%
Price vs SMA 200
+16.1%
Avg volume (3M)
2.04M
Relative volume
0.6
Average dollar volume
$4.11M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
266.16M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
4.2×
reciprocal yield 23.8%
P / book
6.6
reciprocal yield 15.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-56.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-11
Profitability
9 metricsGross margin
15.7%
Operating margin
-210.8%
Trailing 12 months
Net margin
-238.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$247.44M
Net income (TTM)
−$280.16M
Trailing 12 months
Diluted EPS (TTM)
$-1.06
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+118.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$117.39M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-374.3%
Return on assets
-56.8%
Debt / equity
—
Current ratio
4.9
EBITDA (TTM)
−$238.85M
Free cash flow (TTM)
—
Quick ratio
4.4
Interest coverage
-5.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$171.41M
Total assets
$493.23M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$225.61M
Capital expenditures (TTM)
$7.12M
R&D (TTM)
$112.63M
SG&A (TTM)
$153.19M
Stock compensation (TTM)
—
R&D / revenue
95.9%
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
83
13F filer change QoQ
-1
Institutional ownership
49.8%
Short interest
3 metricsShort interest
3.1%
Latest settlement · 4.8 days to cover
Days to cover
4.8d
Short-squeeze score
61 / 100
Insider activity
2 metricsNet insider buying (90D)
−$15,682
Insider-sentiment score
56 / 100
Risk flags
1 metricsGoing concern
—